NTT-CORPORATION
6.9.2022 11:41:37 CEST | Business Wire | Press release
NTT Corporation (NTT, Head office: Chiyoda-ku Tokyo; President & CEO: Akira Shimada) has developed a digital coherent signal processing circuit and optical device that achieves the world's largest capacity of 1.2 Tbit/s per wavelength for optical transmission, which is 1.5 times faster than before. With this development, NTT tackles the challenge of achieving advanced optical transmission technology that can economically and significantly expand the capacity of existing systems while reducing the power consumption of communication devices.
The technology has also achieved the world’s highest optical signal modulation speed of 140 Giga baud and enables double the previous world record optical transmission distance of 800 Gbit/s. As a result, the capacity of optical transmission systems will increase by 12 times and the power consumption per bit will be reduced to 10% of the widely used commercial system. The improvements in the performance and power consumption of optical transmission systems should contribute to the All-Photonics Network foundational to the IOWN1 concept.
Our digital coherent signal processing circuit combines cutting-edge coded modulation with transmission performance approaching the theoretical limit and newly developed forward error correction that can correct bit errors in large amounts of data with low power consumption. This results in flexible coded modulation that maximizes the potential of high-speed optical devices. Furthermore, by utilizing a power-efficient algorithm to equalize signal distortion in the optical fiber transmission channel and the advanced CMOS processes, we have achieved a digital signal processing of 1.2 Tbit/s per wavelength with low power consumption.
The transceiver consists of a cutting-edge digital coherent signal processing circuit and a 140-Giga baud class optical device with the world's widest-class opto-electrical response bandwidth. In our approach, by increasing the modulation speed from 100 Giga baud to 140 Giga baud, higher resistance to waveform distortion and optical amplification noise caused by transmission could be achieved. As a result, the previous record transmission distance of 800 Gbit/s signals can be extended by more than twice that of the 100 Giga baud devices.
Toward the development of IOWN, NTT aims to create an innovative network with high capacity, low latency, flexibility, and low power consumption by continuing to expand and develop end-to-end photonics technology. We will promote the creation of economical, large-capacity, low-power-consumption networks by leveraging advanced optical transmission systems based on innovative technology. We also intend to collaborate with both international and domestic partners so that our developments can be valuable and beneficial for communities worldwide. You can access the full report about this development here.
1 IOWN: https://group.ntt/jp/newsrelease/2019/05/09/190509b.html (Japanese)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220905005467/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
